Clinical features and treatment of maturity onset diabetes of the young (MODY) by Gardner, Daphne SL & Tai, E Shyong
© 2012 Gardner and Tai, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2012:5 101–108
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Clinical features and treatment of maturity  
onset diabetes of the young (MODY)
Daphne SL Gardner1
E Shyong Tai2
1Department of Endocrinology, 
Singapore General Hospital, 
2Department of Endocrinology, 
National University Hospital, 
Singapore
Correspondence: Daphne SL Gardner 
Department of Endocrinology, Singapore 
General Hospital, Block 6, Level 6, 
Outram Road, Singapore 169608 
Tel +65 6321 4523 
Email daphne.gardner@sgh.com.sg
Abstract: Maturity onset diabetes of the young (MODY) is a heterogeneous group of disorders 
that result in β-cell dysfunction. It is rare, accounting for just 1%–2% of all diabetes. It is often 
misdiagnosed as type 1 or type 2 diabetes, as it is often difficult to distinguish MODY from these 
two forms. However, diagnosis allows appropriate individualized care, depending on the genetic 
etiology, and allows prognostication in family members. In this review, we discuss features of 
the common causes of MODY, as well as the treatment and diagnosis of MODY.
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Introduction
Maturity onset diabetes of the young (MODY) was a term first used in the 1970s1,2 
to describe inheritable diabetes distinct from type 1 (insulin-dependent) and type 2 
(noninsulin-dependent) diabetes. In these initial reports, MODY patients displayed a 
familial form of noninsulin-dependent diabetes, which showed autosomal dominant 
inheritance and which typically presented before the age of 25 years. The molecular 
genetic basis of MODY was subsequently recognized in the 1990s,3–7 indicating 
that genetic mutations result in diabetes primarily through their effects on β-cell 
  dysfunction. The clinical features of patients with MODY are now known to be 
  heterogeneous, depending on the genetic etiology.
To date, there are mutations in at least nine different genes (Table 1) that result in 
the MODY phenotype, which accounts for approximately 1%–2% of patients diag-
nosed with diabetes.8 This prevalence is likely underestimated, since large population 
screening studies have not been performed. Depending on the genetic etiology, the 
different genetic subtypes differ in terms of age of onset, pattern of hyperglycemia, 
response to treatment, and extra-pancreatic manifestations. Thus, it would be more 
appropriate to use the correct monogenic names for young-onset diabetes, since MODY 
is not a single entity.
Mutations in the genes encoding the nuclear transcription factor 1 homeobox A 
(HNF1A), the hepatocyte nuclear factor 4 homeobox (HNF4A), and the enzyme glu-
cokinase (GCK) are the most common causes of MODY, representing 52%, 10%, and 
32% of MODY cases in the UK, respectively.9 The reported prevalence of these causes 
varies across countries due to differences in the frequency of screening for diabetes. For 
example, in countries where glucose is more frequently performed to screen for diabetes 
in asymptomatic individuals, GCK mutations (manifesting with mild hyperglycemia) 
are detected more often. As a consequence, GCK mutations predominate in countries 
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such as Germany, Italy, France, and Spain.10,11 MODY has 
also been described in other ethnic groups.6,12 However, 
prevalence in other ethnicities may be underrepresented, 
since Asian patients make up only 0.5% of UK referrals for 
MODY testing, even though there is a significantly higher 
prevalence of diabetes in Asian patients.12
One  of  the  challenges  in  diagnosing  MODY  is 
  distinguishing individuals with MODY from those with 
type 1 or type 2 diabetes, as the clinical features may be 
similar and there is often an overlap in phenotypes. This 
review discusses the features of the most common forms 
of MODY, concentrating on patients presenting with young 
onset diabetes (between the ages of 10 and 40 years), as 
well as treatment options. We also discuss the selection of 
individuals for further genetic testing. Neonatal forms of 
diabetes, and other forms of monogenic diseases associated 
with diabetes, such as Donohue syndrome or lipodystrophy, 
are beyond the scope of this review.
How do patients with MODY  
present clinically?
Patients with MODY often have one or more of these 
f  eatures: a strong family history of diabetes of any type, 
insulin independence, absence of autoantibodies for 
pancreatic antigens,13 and evidence of endogenous insu-
lin production (detection of measurable C-peptide in 
the presence of hyperglycemia, low insulin requirement 
[,0.5 units/kg/d], or a lack of ketoacidosis when insulin 
is omitted outside the honeymoon period [typically 5 years 
following the   diagnosis of   diabetes]). These features are 
atypical for type 1 diabetes, thus increasing the probability 
of monogenic   diabetes. However, in those with apparent 
type 2 diabetes, the absence of insulin resistance features 
(a lack of obesity, the absence of acanthosis nigricans, nor-
mal triglyceride levels, or elevated or normal high-density 
lipoprotein cholesterol [HDL-C]) can indicate the presence 
of monogenic β-cell forms of diabetes.
There are distinct phenotypes in clinical presentation, 
and these are dependent on the genetic etiology. The vari-
ous genes involved, and the associated clinical features, are 
described and then summarized in Table 1.
Genes involved in MODY
HNF1A
Mutations in the HNF-1α (or HNF1A) gene are the most 
common cause of MODY in the UK,14 and they are a com-
mon cause of MODY in other European countries, such 
as Germany,15 Finland and Sweden,16 Italy,17 and Spain.18 
  Mutations in HNF1A have also been described in the 
Canadian,19 North American,20 Japanese,21 and Chinese  22 
populations.
The HNF1A gene consists of ten exons and studies 
of HNF1A knockout animals show a reduction in the key 
steps of glucose transport and metabolism.23 In β-cell lines, 
mitochondrial metabolism also appears to be reduced.24,25 
These HNF1A mutations demonstrate a high penetrance, 
Table 1 Classification of single gene mutations resulting in monogenic diabetes
Gene Prevalence amongst  
those with MODY
Other clinical features
HNF1A 30%–50%* Common mutation. Highly penetrant. Large (.5 mmol/L) rise in 2-hour glucose levels on 75 g–OGTT. 
Progressive β-cell failure. Sensitivity to sulphonylureas.
GCK 30%–50%* Common mutation. Raised fasting glucose levels, with small (,3 mmol/L) rise in 2 hour glucose 
following 75 g–OGTT. Mild hyperglycemia; generally does not require treatment.
HNF4A 5% Presents in similar manner to HNF1A mutations. Associated with higher birth weight and transient 
neonatal hypoglycemia. Progressive β-cell failure. Sensitivity to sulphonylureas.
HNF1B 5% Characterized by renal disease. Urogenital tract abnormalities in females.
iNS ,1% wide clinical spectrum. Most present with neonatal diabetes, but may also present in early childhood 
and adulthood.
iPF1 ,1% Average age of onset is 35 years.7 iPF1 regulates early pancreatic development. Pancreatic agenesis 
seen in homozygotes and compound heterozygotes.83,84
NEUROD1 ,1% (fewer than  
five families reported)
very rare, adult onset (mid-20s). Reduced insulin production (developmental β-cell dysfunction). 
individuals may be overweight or obese, similar to type 2 diabetes.
CEL ,1% (fewer than  
five families reported)
Very rare, adult onset (mean age 36 years). Exocrine pancreatic insufficiency (dysfunction of the 
mature acinar cell). Pathophysiology of endocrine dysfunction not clear.
PAX4 ,1% (fewer than  
five families reported)
Only two families described.
Note: *Dependent on the populations studied.
Abbreviations: HNF1A, hepatocyte nuclear factor 1 homeobox A; GCK, glucokinase; HNF4A, hepatocyte nuclear factor 4 homeobox A; HNF1B, hepatocyte nuclear factor 
1 homeobox B; iPF1, insulin promoter factor 1; NEUROD1, neurogenic differentiation 1; CEL, carboxyl ester lipase; PAX4, paired box 4.
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with 63% of carriers developing diabetes by 25 years of 
age, 79% by 35 years of age, and 96% by 55 years of age. 
The age at diagnosis is partly determined by the location of 
the   mutation: those with mutations in the terminal exons 
(8–10) are diagnosed on average 8 years earlier than those 
with mutations in exons 1–6.26
Typically, patients heterozygous for HNF1A mutations 
present in adolescence, or early adult life, with progressive 
β-cell failure and increasing hyperglycemia. In fact, β-cell 
dysfunction is seen to occur before the onset of diabetes 
in HNF1A mutation carriers. Even when blood glucose is 
in the normal range, HNF1A mutation carriers are seen to 
have a lower insulinogenic index and a lower early insulin 
response when compared to non-mutation carriers in the 
same family.27 This is clear when the individuals undergo 
an oral glucose tolerance test, with the 2-hour glucose level 
frequently being more than 6 mmol/L higher than the fast-
ing level, even when the fasting glucose level is less than 
6 mmol/L.28 Another feature of this group of patients is a low 
renal threshold for glucose. Glycosuria has been observed 
in young nondiabetic HNF1A mutation carriers.27 This is 
thought to be due to a reduced expression of the sodium-
  glucose transporter-2, reducing glucose re-absorption 
through the proximal tubule.29
Due to its progressive nature, those with HNF1A muta-
tions are at considerable risk of microvascular and macro-
vascular complications,30,31 similar to those with type 1 and 
type 2 diabetes. The frequency of hypertension appears to be 
similar to type 1 diabetes.30 Raised, rather than low, HDL-C 
levels are observed in HNF1A MODY patients, which 
is potentially a useful feature for distinguishing between 
MODY and type 2 diabetes.32
Treatment
Another important distinguishing feature of HNF1A muta-
tions is that afflicted individuals are extremely sensitive to 
the hypoglycemic effects of sulphonylureas.33–35 A random-
ized cross-over trial, which assessed glycemic responses to 
the sulphonylurea gliclazide and the metformin, compared 
patients with HNF1A mutations and type 2 diabetes, who 
were matched for fasting glucose and body mass index.36 
While the effects of metformin and gliclazide were similar 
in those with type 2 diabetes, there was a fivefold greater 
response to gliclazide than metformin in those with HNF1A 
mutations. In addition, the response to gliclazide was four-
fold greater in these individuals than in type 2 diabetes 
patients, while the response to metformin remained similar 
in both groups.
This finding has large implications, particularly for those 
previously misdiagnosed with type 1 diabetes, as they may 
be able to discontinue insulin therapy and be treated with 
sulphonylureas without risk of ketoacidosis,37 even after 
insulin treatment for a mean of 20 years. A further report, 
where 34 patients were taken off insulin and given sulphony-
lurea after a diagnosis of HNF1A MODY, showed that 24 of 
34 patients were able to remain off insulin for over 3 years, 
with no deterioration in glycemic control.38 Nateglinide has 
been used in 15 patients with HNF1A MODY, suggesting 
that prandial secretagogues may be a useful alternative.39 
Although control may be maintained for many years, most 
patients eventually progress to insulin treatment.
GCK
GCK mutations are another common cause of MODY, and 
those with heterozygous mutations demonstrate mild, stable 
fasting hyperglycemia (5.5–8.0 mmol/L) that shows little 
deterioration with age. Patients are generally asymptomatic, 
and hyperglycemia is commonly discovered during routine 
screening, for example during pregnancy or through insur-
ance medicals.
GCK catalyzes the rate-limiting step of glucose phos-
phorylation, thus enabling the β-cell and the hepatocyte 
to respond appropriately to the degree of glycemia.40 
  Heterozygous inactivating mutations reset the glucose 
threshold for the insulin secretion being regulated to a higher 
level, producing a higher fasting glucose level.41 The insulin 
production is adequate; therefore, the glucose levels in these 
individuals rapidly return to normal when they are given an 
oral glucose load. Most patients with mutations in the GCK 
have a small increase in plasma glucose (,3 mmol/L in 
70% of patients) 2 hours after an oral glucose load.28
The majority of patients with MODY due to GCK muta-
tions maintain glycated hemoglobin (HbA1c level) below 
8%,42 and observational studies suggest that these patients 
do not develop diabetes-related microvascular complica-
tions, despite exposure to hyperglycemia over an average 
period of 50 years.43,44 Although there are little data on long-
term macrovascular complications, one larger cohort study 
seems to suggest there is no increase in the prevalence of 
dyslipidemia or hypertension in these patients, which raises 
the possibility that their macrovascular risk may not be sig-
nificantly elevated.43
Treatment
Given the mild hyperglycemia, the absence of long-term 
microvascular complications, and the observation that 
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  treatment has little effect on glycemia in this group of 
patients,45 the general consensus is that the majority of these 
patients do not require treatment.46 The only exception is dur-
ing pregnancy, in which insulin may be required to prevent 
excess fetal growth.47 This is also dependent on whether 
the fetus has inherited the GCK mutation (50% chance). If 
it does not inherit the same GCK mutation as the mother, 
it will respond to maternal hyperglycemia by producing more 
insulin, resulting in excess growth. Conversely, if it does 
inherit the GCK mutation, it will produce normal amounts 
of insulin, despite the higher level of glycemia, and thus 
growth will be normal. The glucose-sensing threshold for 
insulin production is upregulated, such that if a person with 
the GCK mutation is given exogenous insulin, endogenous 
insulin secretion is lowered so that the glucose is maintained 
at their homeostatic set point. Thus treatment with insulin 
in this situation requires higher than replacement doses to 
lower the fasting glucose.47
HNF4A
While HNF1A and GCK mutations are the most common 
mutations encountered in monogenic diabetes, HNF4A muta-
tions are much less common, reportedly representing 2%–5% 
of all MODY cases.48–50 They present in a similar manner to 
HNF1A carriers, with progressive β-cell dysfunction, and 
many patients develop diabetes by the age of 25.
The detection of HNF4A mutation carriers amongst 
those presenting with type 2 diabetes may be difficult. 
Useful clinical features include the presence of a family 
history of diabetes, in particular when onset is before the 
age of 40, and the absence of insulin resistance markers or 
obesity in an individual with young-onset type 2 diabetes.51 
Using these criteria, and excluding those with features sug-
gestive of GCK deficiency, HNF4A mutations have been 
found to be as high as 10%–29% amongst those negative 
for HNF1A mutations.51,52 HNF4A mutations should be 
considered when HNF1A analysis does not detect a muta-
tion, but the clinical features are strongly suggestive of 
HNF1A mutations.53
HNF4A mutation carriers may also have a lower serum 
HDL-C, possibly due to reduced ApoA2 transcription,51 
resulting in lipid profiles not dissimilar to those with type 2 
diabetes. In addition, HNF4Amutation carriers tend to have 
a higher birth weight (mean 800 g greater), with 56% having 
macrosomia. Transient neonatal hypoglycemia (15% of 
mutation carriers) may precede the onset of diabetes at a 
later age.54 This is thought to reflect HNF4A-induced hyper-
insulinism during fetal and neonatal life, with a switch to 
defective insulin secretion later in life. The mechanism for 
this remains unclear.
Treatment
As β-cell dysfunction is progressive, treatment is required, 
and low-dose sulphonylureas (12.5% or less of the maximum 
licensed dose) appear to be effective for HNF4A diabetes,51 
which is similar to the response seen with HNF1A diabetes. 
In fact, treatment efficacy with sulphonylureas appears to 
be sustained even after three decades.55 Similar to those 
with HNF1A mutations, the homeostatic model assessment 
analysis suggested a marked β-cell defect in these subjects, 
but no reduction in insulin sensitivity.
Extra-pancreatic features  
and other etiologies
There are several rarer mutations resulting in diabetes-related 
extra-pancreatic features. Among this group of disorders, 
one of the more common mutations is in hepatocyte nuclear 
factor 1 homeobox B (HNF1B).
HNF1B
HNF1B is encoded by the TCF2 gene and plays a role in 
the tissue-specific regulation of gene expression in various 
organs, such as the liver, kidney, intestines, and pancreatic 
islets, thus influencing their embryonic development.56
Patients can develop renal disease, characterized by 
renal cysts, renal dysplasia, renal-tract malformations, or 
hypoplastic glomerulocystic kidney disease.57 Renal involve-
ment appears to be heterogeneous with a tubulointerstitial 
profile at presentation, and slowly progressive renal decline 
throughout adulthood in the absence of diabetic nephropathy. 
In addition, pancreatic atrophy, genital tract abnormalities 
in females, and abnormal liver levels have been observed in 
afflicted individuals.58–60 Birth weight is reduced by 800 g 
due to reduced insulin secretion in utero.61 About half of the 
HNF1B mutation carriers present with early-onset   diabetes, 
which is similar to those with HNF1A mutations.62 Impor-
tantly, spontaneous de novo mutations occur relatively 
frequently; thus, testing for HNF1B mutation should not 
be discouraged by the absence of a family history of renal 
disease or diabetes.57
Other causes of diabetes  
with extra-pancreatic features
These are extremely rare and include the Wolfram syn-
drome, also known as the DIDMOAD (diabetes insipidus, 
diabetes mellitus, optic atrophy, and deafness) syndrome, 
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the   thiamine-responsive megaloblastic anemia syndrome, and 
maternally inherited diabetes with deafness.63 The latter dis-
order is due to mutations within the mitochondrial genome, 
resulting in manifestations in metabolically active organs. In 
particular, in the case of diabetes, mitochondrial dysfunction 
in the pancreatic islets leads to abnormal β-cell function, 
reduction in β-cell mass, and insulin deficiency.64,65 Afflicted 
individuals can manifest with mitochondrial myopathy, 
encephalopathy, lactic acidosis, and stroke-like   episodes. 
Although treatment with dietary modification and oral anti-
glycemic agents may help initially, insulin will usually be 
required eventually.66 Metformin is usually avoided due to 
the theoretical risk of exacerbating lactic acidosis.
Other etiologies
Mutations in other genes (predominantly transcription 
factors), such as neurogenic differentiation 1 (NEUROD1)67–69 
and paired box 4 (PAX4),70 are exceedingly rare causes of 
MODY; thus, limited data is available.   Mutations in the 
gene encoding the enzyme carboxyl ester lipase have been 
shown to result in both diabetes and pancreatic exocrine 
dysfunction.71,72
why is the diagnosis  
of MODY important?
Although the diagnosis of MODY is rare, and constitutes 
only a small proportion of the people afflicted with diabetes, 
it has important implications. For the individual, it informs 
optimal treatment options in some instances (eg, the efficacy 
of sulphonylureas in HNF1A and HNF4A mutations) and 
obviates the need for treatment in others (in the case of mild 
hyperglycemia in GCK mutations). It also allows the future 
course of the illness to be predicted. It can guide management 
for the next generation (as in the case of a pregnant GCK 
patient). Furthermore, once the mutation in the index case is 
known, this information can be used to quickly and readily 
confirm the diagnosis in affected family members.
Interestingly, common variants in several genes involved 
in MODY are associated with an increased risk for developing 
type 2 diabetes. In recent meta-analyses conducted on type 
2 diabetes in East Asians and South Asians, HNF4A single 
nucleotide polymorphisms were found to be associated with 
increased risk for type 2 diabetes.73,74 Similarly, an insulin 
(INS) common variant has also been implicated in increased 
type 2 diabetes risk.75 Elucidating the pathophysiology behind 
monogenic forms of diabetes can help unravel some of the 
mysteries underlying the pathogenesis of the more common 
type 2 diabetes.
How is MODY diagnosed?
MODY is diagnosed through sequencing of the suspected 
gene, and detecting a mutation. However, molecular genetic 
testing is expensive and not widely available. It is also evident 
from the description of the various MODY phenotypes that 
the clinical spectrum is extremely varied and has significant 
overlap with both common types of diabetes, making it a 
challenge to identify MODY patients. As a consequence, 
many patients with MODY remain undiagnosed. A targeted 
selection of individuals for genetic testing is necessary to 
improve the yield of diagnosis, particularly in situations 
where there are limited resources.
How can we identify patients  
for testing using clinical criteria?
Individuals with a strong family history of diabetes, 
p  resenting from the second to the fifth decade, should prompt 
further assessment. The best clinical practice guidelines pro-
duced in 2008 advocate assessment for MODY, particularly 
when the age of presentation for diabetes is ,25 years old.53 
The next step would be to look for features inconsistent with 
the diagnosis of type 1 diabetes (insulin independence, per-
sistently detectable C-peptide, and negative antibody status) 
or type 2 diabetes (lack of insulin resistance and its markers). 
Even using these criteria, the detection of MODY is low.76
Specific features may increase the likelihood of cer-
tain genetic defects and improve the cost-effectiveness of 
targeted molecular diagnostic testing. This will hopefully 
improve detection rates for this currently under-diagnosed 
condition. For example, a low renal threshold (glycosuria 
at blood glucose levels ,10 mmol/L) or a large increase of 
.5 mmol/L on OGTT may raise the suspicion of a HNF1A 
mutation. Recently, genome-wide association studies have 
found that common variants mapping near the HNF1A gene 
are associated with small alterations in serum C-reactive 
protein (CRP) levels in healthy individuals.77 The presence of 
HNF1A binding sites on the CRP promoter,78 and the loss of 
CRP expression resulting from a loss of HNF1A binding,78 
further supports the hypothesis that HNF1A expression 
and binding influences CRP expression. Motivated by this 
finding, high-sensitivity CRP was studied and found to be 
significantly lower in individuals with HNF1A gene muta-
tions.79 This has since been replicated in larger cohorts.80,81 In 
combination with clinical criteria, the use of high-sensitivity 
CRP has been shown to greatly improve sensitivity in the 
detection of HNF1A MODY (up to 90%), without much 
loss of specificity.81 As another example, mutations in the 
GCK gene result in mild fasting hyperglycemia or a small 
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  increment of ,3 mmol/L of glucose on the OGTT.53 However, 
it is clear that many MODY individuals remain undiagnosed,9 
or do not fulfill the criteria for referral.82
Conclusion
MODY is a genetically and clinically heterogeneous group 
of conditions. Its identification remains a challenge for 
physicians, and the condition is largely underdiagnosed. 
Yet diagnosis has important implications for the individual, 
allowing individualized care to be tailored to the underlying 
genetic causes, and it provides information about the natural 
history of the disease in individuals. Knowledge of these 
rare causes of diabetes, the use of additional clinical clues, 
and other biomarkers will hopefully improve its detection 
rates, allowing appropriate care and advice to be given to the 
afflicted person and their family members.
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